Past Speakers


Ming Zheng


Vice President of Clinical Science and
Medical Affairs
Shanghai MicroPort Medical (Group) Co., Ltd.

Xiaoming Feng


Researcher
National Institutes for Food and
Drug Control

YUZELI


RAC, Global
YUZELI MEDTECCONSULTANT INC.

Yongqiang Hao


Chief Physician
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

Alex Jiang


Quality Director of APAC
Smith & Nephew

Andy Yin


R&D director
Shanghai Innovation and R&D Center of Blue Sail Medical

Xiangdan Kim


Global Regulatory Affairs Expert
Lepu Medical Technology
(Beijing)Co.,Ltd.

Lane JI


Medical Devices Director of BSI China
BS

Tamara Yuan


APAC QA/QC VP
Zimmer Biomet Inc.

Li Shen


Director of Cardiovascular
Secretary-General of CCI
Zhongshan Hospital Affiliated to Fudan University

Yulin Weng


Founder and CEO
DK MEDTECH

Ben Zhao


Senior Reliability Engineer
Medtronic,China R&D Center

Jian Fong TAN


Chief Technology Officer
Peijia Medical Limited

Cheng Yunzhang


Vice President, School of Medical Instrument
and Food Engineering, University of Shanghai
for Science and Technology (USST)
Director of Shanghai Interventional Medical
Device Engineering Technology Research Center

Jack Li


CTO
Shanghai HeartCare Medical
Technology Co., Ltd

Zikai Hua


Director of Intelligent Components Research
Center, Shanghai University
Director of Orthotek Lab of Shanghai University

Thomas Row


Sr. Industrial Designer
Medtronic Technology Center, Shanghai

Pengfei Yang


Deputy director of cerebrovascular
disease center
Changhai Hospital of The Second
Military Medical University

Hongfeng Ju


General Manager
WEGO

Guangmei Wu


Director of 3D Printing Asia Programs
Johnson & Johnson

Caimei Wang


Director of R&D Center
Beijing AK Medical Co., Ltd.

Jack Zhou


Chief Operating Officer
DiNova-Hangzhou Wei Qiang Medical
Technology Co., Ltd.

Sean Kang


General Manager
Sino Shenchang Medical Technology Co., Ltd.

Xuanyong Liu


Researcher, Director of Biomaterials and
Tissue Engineering Research Center
Shanghai Institute of Ceramics,
Chinese Academy of Sciences

Ke Yang


Researcher
Institute of metal research,
Chinese Academy of Sciences

Daxin Wen


Sales Engineer
Coherent (Beijing) Commercial Co.,Ltd

Shen Liu


Head of Medical Industry
GF Machining Solutions

Alex Han


Product Sales Manager
Carl Zeiss Shanghai Co.,Ltd

Jeff Zhang


Lab Weighing Application Specialist
Sartorius

Lynn Jiao


Vice President &
China Executive Director
Advanced Medical Technology
Association (AdvaMed)

PARTIAL LIST OF ATTENDING COMPANIES


Guests' Essential Views


Xiaoming Feng
Researcher
National Institutes for Food and Drug Control

 

 

 

Registration and Inspection of Medical Devices
under the New Regulations

To innovate medical device products, we should pay attention to inspection methods and research. Why? Because for many innovative medical devices, there is no standards to follow, and the inspection methods are uncertain or absent, it is necessary to do research on inspection methods and inspection methodologies while innovating medical devices. For personalized and customized products, I can't use this product for destructive inspection, which will destroy the product. Correct inspection should pay more attention to our product quality control in the middle stage of the processing process. Also, we may pay more attention to rapid inspection methods as it is impossible for us to use some slow inspection methods, which require to wait for the inspection results before we release them, so we need to do some online inspection and rapid inspection methods.

Hong Qian
Minister
Center for Drug Certification and Evaluation
Shanghai Municipal Food and Drug Administration

 

 

 

Analysis if medical device technical review-
related policies and common issues

Since June 1, the newly revised Regulations on the Supervision and Administration of Medical Devices has been officially implemented, and it once again emphasizes the quality management of medical devices in the whole life cycle. The registrant or filer is responsible for the safety and effectiveness of medical devices in the whole process of development, production, operation and use according to law. As for the self-test report, it is the most basic requirement that the information submitted should be legal, true, accurate, complete and traceable. In terms of innovation, China encourages innovation greatly, formulates medical device industry plans and policies, and gives priority to the review and approval of innovative products. China shall improve the innovation system of medical devices and support some basic research and applied research of our medical devices, including the promotion and application of new products.

Ming Zheng
Vice President of Clinical Science and Medical Affairs
Shanghai MicroPort Medical (Group) Co., Ltd.

 

 

 

Global planning and layout of clinical trials and leadership in science
for medical device companies with China joining the ICH

If you want to join ICH, this is a better opportunity, and also there are many challenges at the same time. Only when you go abroad can you become stronger and become a better enterprise. Second, the international layout of clinical trials comes with overall layout and individual layout, that is to say, this layout should follow many principles, for example, what is the clinical path, and achieving scientific top-level design, so that medical devices can successfully cope with the market. Third, the layout of scientific leadership for core products should be carried out simultaneously, because this is a very high and wide moat. If you have a good layout of this moat, it will be very fast to improve the products and global leadership of the company, especially such a very core and very effective one.

Jack Li
CTO
Shanghai HeartCare Medical Technology Co., Ltd

 

 

 

Future Is Now:
Development of Innovative Interventional Treatment of Stroke

The volume of devices for embolization treatment, stenosis treatment, prevention and bleeding treatment is very large. If we calculate this volume according to the current market price and the devices sold in the market, by 2025, the volume of devices for embolization thrombectomy and aspiration will be about 13 billion, and the volume of devices for stenosis treatment will be about 2.4 billion, which should actually be more than that. In terms of prevention, the devices are mainly used for atrial fibrillation and left atrial appendage occlusion, seemingly 2 billion at present. In fact, due to the influence of medical insurance, devices for left atrial appendage occlusion have not really been popularized, and those for coronary artery and cranial nerve are not well combined. There is still a long way to go before this prevention could really be carried out well. In terms of bleeding, coils are old products, with a scale of about 9 billion, and there will be large space for growth in the future.

Jian Fong TAN
Chief Technology Officer
Peijia Medical Limited

 

 

 

Transcatheter Technologies for Structural Heart:
Repair or Replacement?

Should mitral valve be replaced or repaired? Five years ago, it must have been a replacement, but now there are many people who are optimistic about repair. This is a dynamic situation. Today, five years later, is a different situation, depending on what direction the next equipment research and development is. If we answer the question on tricuspid valve, should it be replaced or repaired? This is even harder to answer. The answer may intend to be repair, just a little. It may not be such a situation in five years, but at least now I personally think it is such a situation. To sum up, to
repair or replace, we need to judge whether it is aortic valve or mitral/tricuspid valve. Replacement is the mainstream in terms of aortic valve, and repair accounts for a large proportion in term of mitral valve, but we must never forget the importance of TMVR in replacement of mitral valve. After all, not all patients are suitable for clip surgery.

Hongfeng Ju
General Manager
WEGO

 

 

 

Thinking and Practice of Intelligent Manufacturing
Transformation in Medical Device Enterprises

We are followers of innovation, slowly transitioning to the leader of innovation, which is a great challenge for us. Based on the above challenge, we think there are two very important points: the first is the value orientation in the whole strategic management process, and the second is the creation of end-to-end data link, which is the strategy of digital transformation. For every medical enterprise, first, in the whole manufacturing management process, the effective unification of man and machine, including the management of production rhythm, moves toward from manufacturing 3.0 to manufacturing 4.0; second, the management of the enterprise itself and its stakeholders, including the upstream and downstream of the value chain; third, the production, supply and marketing of the enterprise itself, including three-level management and four-level management, and the value chain coordination within the group, which is very important.

Pengfei Yang
Deputy director of cerebrovascular disease center
Changhai Hospital of The Second Military Medical University

 

 

 

Innovation in clinical trials and neurointerventional devices

I think nerve intervention can account for one fifth of the future nerve intervention now. We must find out where the next potential point is and who will explore this point? Clinicians shoulder a great mission. When we explore this point, I think the business community has invested more in all aspects. Of course, how can you innovate? Subversive innovation - doctors should participate in subversive innovation-is the point that you find, and then firmly do clinical trials towards while making subversive product research and development, which is the real subversive innovation. I don't mean that this will work. I just tell you, as clinicians, what are our thoughts on medical device innovation? What we have to do is to expand the scope of our industry.